vs
Side-by-side financial comparison of Maison Solutions Inc. (MSS) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $27.5M, roughly 1.0× Sanara MedTech Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -18.0%, a 12.1% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -10.9%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs 21.8%).
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
MSS vs SMTI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $27.5M |
| Net Profit | $-5.0M | $-1.6M |
| Gross Margin | 23.4% | 93.2% |
| Operating Margin | -4.9% | 23.5% |
| Net Margin | -18.0% | -5.9% |
| Revenue YoY | -10.9% | 4.6% |
| Net Profit YoY | -1840.5% | 5.3% |
| EPS (diluted) | $-0.23 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.6M | $27.5M | ||
| Q3 25 | $27.2M | $26.3M | ||
| Q2 25 | $34.4M | $25.8M | ||
| Q1 25 | $32.3M | $23.4M | ||
| Q4 24 | $29.4M | $26.3M | ||
| Q3 24 | $28.2M | $21.7M | ||
| Q2 24 | $16.9M | $20.2M | ||
| Q1 24 | $13.6M | $18.5M |
| Q4 25 | $-5.0M | $-1.6M | ||
| Q3 25 | $-1.5M | $-30.4M | ||
| Q2 25 | $-287.4K | $-2.0M | ||
| Q1 25 | $1.0M | $-3.5M | ||
| Q4 24 | $-256.0K | $-1.7M | ||
| Q3 24 | $700.9K | $-2.9M | ||
| Q2 24 | $-2.8M | $-3.5M | ||
| Q1 24 | $-549.0K | $-1.8M |
| Q4 25 | 23.4% | 93.2% | ||
| Q3 25 | 24.1% | 92.9% | ||
| Q2 25 | 9.5% | 92.5% | ||
| Q1 25 | 21.8% | 92.2% | ||
| Q4 24 | 26.9% | 91.4% | ||
| Q3 24 | 28.9% | 90.8% | ||
| Q2 24 | 13.0% | 90.0% | ||
| Q1 24 | 23.4% | 89.8% |
| Q4 25 | -4.9% | 23.5% | ||
| Q3 25 | 0.7% | 11.2% | ||
| Q2 25 | -15.9% | -0.1% | ||
| Q1 25 | 3.7% | -8.9% | ||
| Q4 24 | 3.2% | 18.6% | ||
| Q3 24 | 7.3% | 3.6% | ||
| Q2 24 | -14.4% | -14.3% | ||
| Q1 24 | -2.3% | -8.3% |
| Q4 25 | -18.0% | -5.9% | ||
| Q3 25 | -5.7% | -115.5% | ||
| Q2 25 | -0.8% | -7.8% | ||
| Q1 25 | 3.1% | -15.1% | ||
| Q4 24 | -0.9% | -6.5% | ||
| Q3 24 | 2.5% | -13.2% | ||
| Q2 24 | -16.4% | -17.4% | ||
| Q1 24 | -4.0% | -9.5% |
| Q4 25 | $-0.23 | $-0.32 | ||
| Q3 25 | $-0.08 | $-3.40 | ||
| Q2 25 | $-0.02 | $-0.23 | ||
| Q1 25 | $0.06 | $-0.41 | ||
| Q4 24 | $-0.01 | $-0.18 | ||
| Q3 24 | $0.04 | $-0.34 | ||
| Q2 24 | $-0.16 | $-0.41 | ||
| Q1 24 | $-0.03 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | $2.6M | $46.0M |
| Stockholders' EquityBook value | $11.6M | $5.9M |
| Total Assets | $75.4M | $72.9M |
| Debt / EquityLower = less leverage | 0.22× | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | $1.1M | $14.9M | ||
| Q2 25 | $775.4K | $17.0M | ||
| Q1 25 | $445.4K | $20.7M | ||
| Q4 24 | $355.7K | $15.9M | ||
| Q3 24 | $588.9K | $16.3M | ||
| Q2 24 | $2.1M | $6.2M | ||
| Q1 24 | $9.4M | $2.8M |
| Q4 25 | $2.6M | $46.0M | ||
| Q3 25 | $2.6M | $45.1M | ||
| Q2 25 | $2.6M | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | $2.5M | $30.1M | ||
| Q2 24 | $2.6M | $14.4M | ||
| Q1 24 | $2.6M | $9.7M |
| Q4 25 | $11.6M | $5.9M | ||
| Q3 25 | $10.1M | $6.1M | ||
| Q2 25 | $11.7M | $35.4M | ||
| Q1 25 | $12.0M | $36.7M | ||
| Q4 24 | $10.9M | $39.4M | ||
| Q3 24 | $11.2M | $39.8M | ||
| Q2 24 | $10.5M | $41.7M | ||
| Q1 24 | $13.3M | $43.3M |
| Q4 25 | $75.4M | $72.9M | ||
| Q3 25 | $73.3M | $71.1M | ||
| Q2 25 | $77.4M | $98.8M | ||
| Q1 25 | $82.7M | $96.4M | ||
| Q4 24 | $82.7M | $88.1M | ||
| Q3 24 | $82.1M | $88.5M | ||
| Q2 24 | $82.4M | $73.4M | ||
| Q1 24 | $44.2M | $70.9M |
| Q4 25 | 0.22× | 7.74× | ||
| Q3 25 | 0.26× | 7.33× | ||
| Q2 25 | 0.22× | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 0.23× | 0.76× | ||
| Q2 24 | 0.24× | 0.34× | ||
| Q1 24 | 0.19× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $3.9M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 14.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $3.9M | ||
| Q3 25 | $1.1M | $2.2M | ||
| Q2 25 | $-1.6M | $2.7M | ||
| Q1 25 | $1.7M | $-2.0M | ||
| Q4 24 | $1.1M | $932.0K | ||
| Q3 24 | $3.6M | $2.1M | ||
| Q2 24 | $-2.6M | $-1.4M | ||
| Q1 24 | $-1.4M | $-1.6M |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
